IviGene Overview
- Founded
- 2000
- Status
- Acquired/Merged
- Latest Deal Type
- M&A
IviGene General Information
Description
Owner and operator of a biotechnology company intended to facilitate genetic research for the study of antigens. The company's services focus on incorporating an In Vivo Induced Antigen Technology which uses antibodies present in the blood of patients infected with or recently recovered from infection with a particular pathogen and help generate and screen antibodies that serve as probes to screen a genomic expression library of the pathogen in order to identify proteins that are specifically expressed during an actual human infection, enabling medical researchers to develop and innovate drugs using antibodies for treating and curing chronic diseases and for vaccine diagnostic and pharmaceutical development.
Contact Information
Website
Ownership Status
Acquired/Merged
Financing Status
Formerly Accelerator/Incubator backed
Primary Office
- 12085 Research Drive
- Alachua, FL 32615
- United States
IviGene Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 20-Nov-2006 | 000 | Completed | Startup | ||
| 2. Corporate | 12-Mar-2001 | 000 | 000 | 000 | Completed | Startup |
| 1. Accelerator/Incubator | Completed | Startup |
IviGene Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Ann Perogulske-Fox | Co-Founder | ||
| Jeffrey Hillman Ph.D | Co-Founder & Chief Scientific Officer | ||
| Martin Handfield Ph.D | Co-Founder |
IviGene Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Xtl Biopharmaceuticals | Corporation | Minority | 000 0000 | 000000 0 |